Emily Kimber is a journalist and editorial assistant, specializing in the field of pharmaceuticals and healthcare. With a focus on providing accurate and timely information to industry professionals, Emily's work has been featured in PMLiVE and PharmaTimes Media Ltd. Her articles cover a range of topics including drug approvals, clinical trial results, and regulatory updates.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Emily Kimber's articles mainly focus on healthcare and pharmaceutical industries, with an emphasis on press releases and data citations. To effectively reach out to her, consider offering newsworthy content related to drug trials, FDA approvals, advancements in biopharmaceuticals or cancer treatment. Furthermore, she may be interested in exclusive insights from industry experts regarding the latest developments within these areas.
Given Emily’s wide coverage of pharmaceutical companies and their activities, providing her with exclusive access to insider information about company developments or potential future trends could increase the chances of successful engagement.
As there is no specific geographic focus mentioned for Emily Kimber’s coverage area, it is advisable to tailor pitches that are globally relevant within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Emily Kimber
The deal includes a candidate in phase 1 development for Alzheimer's disease
By: Emily Kimber
Key measures include a £520m life sciences innovative manufacturing fund
By: Emily Kimber
More than 26 million people in the US are affected by the inflammatory skin condition
A new report reveals all
By: Emily Kimber
Approximately 9,280 new cases of the disease are expected to be diagnosed in the US this year
By: Emily Kimber
The company expects to file for regulatory approvals of the drug in this indication next year
By: Emily Kimber
Approximately 49,200 people are diagnosed with lung cancer every year in the UK
By: Emily Kimber
The launch of a new pharmaceutical product depends on a host of determinants and it just takes one factor to send the launch awry
By: Emily Kimber
The inflammatory skin condition affects over 26 million people in the US alone
By: Emily Kimber
The company plans to develop the candidate for autoimmune diseases such as lupus
(833) 317-6278 
